GA
XBI icon

GoalVest Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

GoalVest Advisory’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$9.88K – 440
2024
Q3 		$9.88K Buy
+100
New +$9.82K ﹤0.01% 326
2022
Q3 		– Sell
-74
Closed -$6K – 321
2022
Q2 		$6K Buy
+74
New +$5.55K ﹤0.01% 267

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

GoalVest Advisory's XBI Position: Q4 2024 in Review

GoalVest Advisory sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 100 shares — an estimated $9.88K sold.

GoalVest Advisory first reported a position in XBI in Q2 2022 and held it in 2 quarters. The position peaked at $9.88K in Q3 2024. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

  • GoalVest Advisory reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
  • GoalVest Advisory sold 100 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $9.88K.
  • GoalVest Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 2 quarters.
  • GoalVest Advisory's State Street SPDR S&P Biotech ETF position peaked at $9.88K in Q3 2024.
  • 738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on GoalVest Advisory's 13F filing for Q4 2024, filed 17 Jan 2025.